Pharmacology Researchers Develop a Novel Monoclonal Antibody Medication to Treat

Pharmacology researchers develop a novel monoclonal antibody medication to treat the wet form of age-related macular degeneration.  The antibody binds vascular endothelial growth factor, decreasing abnormal blood vessel formation in the subretinal space.  In a clinical trial, the medication is found to improve visual function.  During the next phase of the study, researchers use only the antigen binding fragment (Fab) of the antibody instead of the whole immunoglobulin.  Which of the following is most likely to be observed with use of the antibody fragments compared to the intact immunoglobulin?

A) Decreased renal excretion of the drug
B) Greater tissue penetration of the drug
C) Higher receptor-mediated uptake by macrophages
D) Increased complement-dependent cytotoxicity
E) Lower affinity for the target antigen

Correct Answer:

Verified

Unlock this answer now
Get Access to more Verified Answers free of charge

Access For Free